Sherry Shen

423 total citations
33 papers, 266 citations indexed

About

Sherry Shen is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sherry Shen has authored 33 papers receiving a total of 266 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 13 papers in Molecular Biology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sherry Shen's work include Cancer Treatment and Pharmacology (8 papers), Metabolism, Diabetes, and Cancer (8 papers) and Advanced Breast Cancer Therapies (7 papers). Sherry Shen is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Metabolism, Diabetes, and Cancer (8 papers) and Advanced Breast Cancer Therapies (7 papers). Sherry Shen collaborates with scholars based in United States, Thailand and Singapore. Sherry Shen's co-authors include Neil M. Iyengar, Dawn L. Hershman, Joseph M. Unger, Cathee Till, Jason D. Wright, Stephen H. Tsang, William E. Barlow, Scott D. Ramsey, Sandra Naaman and Vicky Makker and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and Cancer.

In The Last Decade

Sherry Shen

30 papers receiving 266 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sherry Shen United States 10 111 95 50 50 35 33 266
Agostino Milluzzo Italy 11 34 0.3× 106 1.1× 19 0.4× 18 0.4× 20 0.6× 20 290
Pardeep Aggarwal United States 12 44 0.4× 145 1.5× 38 0.8× 31 0.6× 24 0.7× 12 397
A Hayward Australia 4 39 0.4× 145 1.5× 78 1.6× 37 0.7× 15 0.4× 5 328
Usha Sriram India 8 170 1.5× 150 1.6× 12 0.2× 25 0.5× 15 0.4× 13 435
Stephen J.H. Dobbin United Kingdom 8 83 0.7× 66 0.7× 173 3.5× 58 1.2× 9 0.3× 14 285
Yoshiyuki Kinoshita Japan 10 88 0.8× 108 1.1× 9 0.2× 31 0.6× 11 0.3× 14 449
Irwindeep Sandhu Canada 11 133 1.2× 251 2.6× 10 0.2× 17 0.3× 104 3.0× 65 482
Astin S. Powers United States 7 109 1.0× 57 0.6× 36 0.7× 36 0.7× 46 1.3× 15 273
Qiuxiao Yu China 6 58 0.5× 101 1.1× 14 0.3× 49 1.0× 18 0.5× 11 301
Jindra Windrichová Czechia 11 61 0.5× 59 0.6× 34 0.7× 40 0.8× 57 1.6× 26 288

Countries citing papers authored by Sherry Shen

Since Specialization
Citations

This map shows the geographic impact of Sherry Shen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sherry Shen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sherry Shen more than expected).

Fields of papers citing papers by Sherry Shen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sherry Shen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sherry Shen. The network helps show where Sherry Shen may publish in the future.

Co-authorship network of co-authors of Sherry Shen

This figure shows the co-authorship network connecting the top 25 collaborators of Sherry Shen. A scholar is included among the top collaborators of Sherry Shen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sherry Shen. Sherry Shen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Goetz, Matthew P., Seth A. Wander, Thomas Bachelot, et al.. (2025). ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+/HER2-, ESR1 -mutated, metastatic breast cancer. Future Oncology. 21(11). 1317–1324. 2 indexed citations
2.
Ferraro, Emanuela, Atif J. Khan, George Plitas, et al.. (2024). Abstract PO3-04-07: Characterization of response to first-line chemotherapy, trastuzumab, and pertuzumab among patients with de novo metastatic HER2-positive breast cancer. Cancer Research. 84(9_Supplement). PO3–4. 1 indexed citations
3.
Shen, Sherry, et al.. (2024). Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive (HR+) metastatic breast cancer.. Journal of Clinical Oncology. 42(16_suppl). 1057–1057. 1 indexed citations
4.
Myers, Sara P., Sherry Shen, Stephanie Downs‐Canner, et al.. (2024). Dose dense doxorubicin plus cyclophosphamide in a modified KEYNOTE522 regimen for triple negative breast cancer. npj Breast Cancer. 10(1). 39–39. 6 indexed citations
5.
Shen, Sherry, et al.. (2024). Evaluation of a mobile behavior change program for weight loss in breast cancer survivors. npj Breast Cancer. 10(1). 53–53. 1 indexed citations
6.
Shen, Sherry, et al.. (2024). The Role of Obesity and Inflammation in Breast Cancer Recurrence. Current Breast Cancer Reports. 16(2). 237–250. 2 indexed citations
7.
Shen, Sherry, et al.. (2024). Glucagon-like peptide-1 (GLP-1) agonist use and weight change among patients with breast cancer.. Journal of Clinical Oncology. 42(16_suppl). 10607–10607. 7 indexed citations
8.
Elliott, Mitchell J., et al.. (2024). Enhancing Early-Stage Breast Cancer Survivorship: Evidence-Based Strategies, Surveillance Testing, and Imaging Guidelines. American Society of Clinical Oncology Educational Book. 44(3). e432564–e432564. 2 indexed citations
9.
Shen, Sherry, Weining Ma, David N. Brown, et al.. (2023). HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer. Modern Pathology. 36(11). 100299–100299. 12 indexed citations
10.
Shen, Sherry, Andrea Smith, Bridget N. Kelly, et al.. (2023). Early integration of exercise into breast cancer care: The MSK healthy living program.. Journal of Clinical Oncology. 41(16_suppl). e24047–e24047. 1 indexed citations
11.
12.
Shen, Sherry, et al.. (2023). Incidence, risk factors, and management of alpelisib‐associated hyperglycemia in metastatic breast cancer. Cancer. 129(24). 3854–3861. 15 indexed citations
13.
Rubinstein, Maria M., Sherry Shen, Bradley J. Monk, et al.. (2022). Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer. Gynecologic Oncology. 167(3). 540–546. 8 indexed citations
14.
Shen, Sherry, Azeez Farooki, James Flory, et al.. (2022). Targeting insulin feedback to enhance alpelisib (TIFA): A phase II randomized trial in metastatic, PIK3CA-mutant, hormone receptor–positive breast cancer.. Journal of Clinical Oncology. 40(16_suppl). TPS1113–TPS1113. 3 indexed citations
15.
Shen, Sherry, Maria M. Rubinstein, Kay J. Park, Jason Konner, & Vicky Makker. (2021). Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma. Gynecologic Oncology Reports. 37. 100844–100844. 10 indexed citations
16.
Hershman, Dawn L., Melissa Accordino, Sherry Shen, et al.. (2020). Association between nonadherence to cardiovascular risk factor medications after breast cancer diagnosis and incidence of cardiac events. Cancer. 126(7). 1541–1549. 13 indexed citations
17.
Accordino, Melissa, et al.. (2019). Abstract PD6-10: Association between adherence to cardiovascular medications and cardiovascular events following a diagnosis of early stage breast cancer. Cancer Research. 79(4_Supplement). PD6–10. 2 indexed citations
18.
Shen, Sherry, Joseph M. Unger, Katherine D. Crew, et al.. (2018). Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927). Breast Cancer Research and Treatment. 172(3). 603–610. 33 indexed citations
19.
Shen, Sherry, et al.. (2014). Next-generation Sequencing Revealed a Novel Mutation in the Gene Encoding the Beta Subunit of Rod Phosphodiesterase. Ophthalmic Genetics. 35(3). 142–150. 16 indexed citations
20.
Davis, Richard, et al.. (2013). Bilateral Concordance of the Fundus Hyperautofluorescent Ring in Typical Retinitis Pigmentosa Patients. Ophthalmic Genetics. 36(2). 113–122. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Agostino Milluzzo Breakdown of academic impact, for papers by Pardeep Aggarwal Breakdown of academic impact, for papers by A Hayward Breakdown of academic impact, for papers by Usha Sriram Breakdown of academic impact, for papers by Stephen J.H. Dobbin Breakdown of academic impact, for papers by Yoshiyuki Kinoshita Breakdown of academic impact, for papers by Irwindeep Sandhu Breakdown of academic impact, for papers by Astin S. Powers Breakdown of academic impact, for papers by Qiuxiao Yu Breakdown of academic impact, for papers by Jindra Windrichová
Rankless by CCL
2026